Viatris

What Viatris does

Viatris is a global pharmaceutical company formed in 2020 through the merger of Mylan and Pfizer's Upjohn division, listed on NASDAQ as VTRS and headquartered in Canonsburg, Pennsylvania. It operates across more than 165 countries with a workforce of approximately 30,000-32,000 employees, reaching roughly one billion patients annually through a diversified portfolio spanning generics, established brands, and innovative medicines. Therapeutic coverage includes cardiovascular, CNS/neurology, immunology, ophthalmology, dermatology, GI, and contraception, supported by proprietary drug delivery devices (selatogrel autoinjector), targeted-release formulations (VR-205), and a global commercialization infrastructure called the Global Healthcare Gateway.

The business model combines low-margin generics volume with branded product pricing power and a late-stage innovative pipeline. Revenue is generated through one-time product sales across pharmacy distribution, direct healthcare provider engagement, and digital channels including a GoodRx partnership offering 17 established brands at up to 85% savings through 70,000+ US pharmacies. Collaboration and royalty revenue includes the YUPELRI partnership with Theravance Biopharma. Viatris pursues disciplined capital allocation: $2.2 billion in free cash flow in 2025, $10.3 billion in debt retired since formation, $6.9 billion in non-core divestitures, and a €650 million Eurobond issuance in June 2026 to support pipeline investments.

Strategic activity has shifted toward operational restructuring (10% workforce reduction expected to save $600-700 million annually, Damastown plant closure), pipeline deepening (Idorsia collaboration worth $350 million upfront, Aculys Pharma acquisition), and non-core divestitures (Vitamin Shoppe). Recent regulatory milestones include Japan's first-ever generalized anxiety disorder treatment approval (Effexor SR), FDA NDA acceptances for fast-acting meloxicam and a low-dose contraceptive patch, and ongoing Phase 3 development of selatogrel and cenerimod targeting blockbusters exceeding $1 billion combined. Management projects 5-6% revenue CAGR and over $3 billion in annual free cash flow by 2030.

Name

Viatris

Legal name

Viatris Inc.

Website

https://viatris.com

Company type

Public

Founded year

2020

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Viatris is a global pharmaceutical company formed in 2020 from the merger of Mylan and Pfizer's Upjohn division, operating in 165+ countries with a portfolio of generics, established brands, and innovative medicines reaching approximately one billion patients annually.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Women’s Health & Reproductive Specialty Pharmaceuticals (HLAIACAN), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Nephrology & Urology Pharmaceuticals (HLAIAAAM), Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO), Drug Delivery Connectivity, Sensors & Digital Add-Ons (Smart Caps/Companion Apps) (HLAHAIAM)

Keywords

• Generic pharmaceuticals
• Branded generics
• Pharmaceutical manufacturing
• Drug delivery devices
• Specialty medicines

Headquarters

HQ city

Pittsburgh

HQ country

United States

HQ region

North America

Offices10 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Generics Portfolio: Viatris produces and markets generic pharmaceuticals spanning multiple therapeutic areas globally, serving as a core revenue driver.
2. Established Brands: Sale of established brand medications including cardiovascular products, CNS treatments, and other branded pharmaceuticals.
3. Innovative Medicines: Revenue from late-stage pipeline products including selatogrel, cenerimod, fast-acting meloxicam, and other innovative therapies in development.
4. Branded Generics: Viatris competes in branded generics market as a major player alongside Teva, Sun Pharma, and Abbott, employing strategies including reformulation and emerging market volume extraction.
5. Collaboration/ Royalty Revenue: Revenue from collaboration agreements including YUPELRI partnership with Theravance Biopharma and royalty streams from partnered products.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

Core offering

Viatris develops, manufactures, and commercializes a global portfolio of generic and branded pharmaceutical products spanning cardiovascular, CNS/neurology, immunology, ophthalmology, dermatology, GI, respiratory, and contraception therapeutic areas, reaching approximately one billion patients annually across more than 165 countries. The company supplies generics, established branded medicines, and a late-stage pipeline of innovative therapies supported by proprietary drug delivery technologies such as autoinjectors, targeted-release oral formulations, and transdermal patches.

Product overview

Viatris is a global healthcare company that offers a dynamic portfolio spanning generics, established brands, and innovative medicines across multiple therapeutic areas. The portfolio includes fast-acting meloxicam for acute pain, selatogrel (Phase 3) and cenerimod (Phase 3) from the Idorsia collaboration for cardiovascular and immunology, VR-205 for IgA nephropathy, and Effexor SR for neurological conditions. Through the Aculys Pharma acquisition, Viatris gained pitolisant and Spydia for CNS therapies in Asia-Pacific. The eye care portfolio includes products from the Oyster Point Pharma and Famy Life Sciences acquisitions. Ophthalmological offerings include phentolamine ophthalmic solution (partnered with Opus Genetics) and varenicline nasal spray. Contraceptive products include XULANE LO and an investigational low-dose estrogen patch. Viatris also commercializes YUPELRI for COPD through its Theravance partnership.

Differentiator

Problem solved

Functional benefit

Brands

• Eye Care Division: Ophthalmology franchise established through acquisitions of Oyster Point Pharma and Famy Life Sciences
• Phentolamine Ophthalmic Solution 0.75%

Products and services

• Fast-acting meloxicam (MR-107A-02) A non-opioid treatment for moderate-to-severe acute pain administered as a fast-acting formulation, supported by Phase 3 clinical trial data from randomized studies following herniorrhaphy and bunionectomy surgeries. Intended for physicians and patients seeking non-opioid acute pain management.
• Selatogrel A potent, fast-acting, reversible, and highly selective P2Y12 inhibitor delivered via a self-administered subcutaneous autoinjector for treatment of acute myocardial infarction, currently in Phase 3 clinical trials. Targeted at AMI patients with a history of heart attack for use during the 'golden hour'.
• Cenerimod A highly selective S1P1 receptor modulator given as an oral once-daily tablet for the treatment of systemic lupus erythematosus (SLE), the result of 20 years of research. Currently in Phase 3 clinical trials under the OPUS program.
• VR-205 (Targeted-Release Budesonide) A targeted-release budesonide oral formulation for the treatment of primary immunoglobulin A nephropathy (IgAN). A Phase 3 trial in Japanese adults demonstrated statistically significant proteinuria reduction. NDA submission is targeted in Japan by the end of 2026.
• Effexor SR (venlafaxine hydrochloride) A serotonin-norepinephrine reuptake inhibitor approved in Japan for the treatment of major depressive disorder and generalized anxiety disorder, becoming the first and only approved GAD treatment option in Japan.
• Pitolisant CNS therapy asset acquired through the Aculys Pharma acquisition for development and commercialization in Japan and other Asia-Pacific markets, supporting Viatris's neuroscience expansion.
• Spydia CNS therapy asset acquired through the Aculys Pharma acquisition for development and commercialization in Japan and other Asia-Pacific markets.
• Phentolamine ophthalmic solution 0.75% An ophthalmic solution for presbyopia and visual disturbances, evaluated in Phase 3 studies (VEGA-3 for presbyopia, MIRA-2 for mydriasis reversal, LYNX-2 for low-light visual disturbances). Held under Viatris's exclusive U.S. commercial rights via a global licensing agreement with Opus Genetics.
• Low-dose estrogen combined hormonal contraceptive weekly patch Investigational contraceptive patch representing a lifecycle advancement of the Xulane contraceptive patch with improved adhesion performance. NDA accepted by the FDA under the 505(b)(2) pathway with a PDUFA date of July 30, 2026.
• XULANE LO Contraceptive patch product developed as a lifecycle advancement to the original Xulane franchise, now shipping commercially.
• YUPELRI (revefenacin) The first and only approved nebulized long-acting muscarinic antagonist (LAMA) for COPD maintenance treatment, commercialized by Viatris in the U.S. under a collaboration agreement with Theravance Biopharma.
• Generic alprazolam (Xanax generic) Generic alprazolam product distributed through U.S. pharmacy channels as part of Viatris's generics portfolio.
• Xanax XR (alprazolam extended-release) Extended-release formulation of alprazolam in Viatris's established brand portfolio, distributed through U.S. pharmacy channels.
• Generics portfolio A global portfolio of off-patent generic pharmaceuticals spanning multiple therapeutic areas, serving as Viatris's core revenue driver. Sold through pharmacy wholesale distribution, PBMs, and healthcare systems worldwide.
• Established Brands Branded pharmaceutical products including cardiovascular, CNS, and other therapeutic categories that are typically differentiated from generics through formulation, dose, combination, or 505(b)(2) data exclusivity, sold globally through pharmacy distribution and via a GoodRx discount partnership in the U.S.
• Varenicline solution nasal spray Investigational nasal spray in Phase 1 development in healthy Japanese adults as part of Viatris's ophthalmology and adjacent pipeline.
• Eye Care Division portfolio Ophthalmology franchise established through the 2023 acquisitions of Oyster Point Pharma and Famy Life Sciences, with the goal of becoming a global leader in eye care. The franchise includes phentolamine ophthalmic solution 0.75% and varenicline nasal spray.

Quantifiable outcome

• VR-205 Phase 3 trial showed 33.75% reduction in urine protein-to-creatinine ratio at 9 months (p<0.001) in IgA nephropathy patients
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature4 records

Partnerships

Nine partnerships are on record, tiered minor and core.

• GSKminorChannel Partner/ Reseller/ Distributor · 29 June 2026Indirect royalty relationship through Theravance Biopharma's stake in TRELEGY net sales ($873 million reported by GSK in Q1 2026), positioning Theravance to receive potential $100 million milestone payment.
• SalesforcecoreTechnology or Integration · 3 June 2026Viatris selected Salesforce Agentforce Life Sciences as its global customer engagement platform to support end-to-end engagement across medical, commercial, and patient support functions in more than 165 countries. Platform provides unified customer views, real-time AI-powered insights, and multichannel engagement capabilities.
• GoodRxcoreGTM or Marketing Partner · 11 March 2026Partnership offering discounts on 17 of Viatris's established brand medications including Lipitor, Celebrex, Viagra, and Norvasc. Accessible through GoodRx platforms at over 70,000 pharmacies nationwide with savings up to 85%. Collaboration aims to improve affordability and access for consumers.
• Aculys PharmacoreOthers · 15 October 2025Viatris completed acquisition of Aculys Pharma, a clinical-stage biopharmaceutical firm focused on neurological treatments. Grants Viatris rights to develop and commercialize pitolisant and Spydia in Japan and other Asia-Pacific markets for neuroscience expansion.
• IdorsiacoreStrategic or Co-development Partner · 28 February 2024Significant global R&D collaboration under which Viatris receives exclusive global development and commercialization rights to selatogrel (potential self-administered treatment for acute myocardial infarction) and cenerimod (novel oral therapy for systemic lupus erythematosus). Both Phase 3 assets with blockbuster revenue potential exceeding $1 billion combined. Viatris paid $350 million upfront with potential development, regulatory, and sales milestone payments and tiered royalties.
• Oyster Point Pharma and Famy Life SciencescoreOthers · 3 January 2023Established new Eye Care Division with acquisitions valued at approximately $695 million. Oyster Point Pharma acquired at $11 per share including CVR. Aiming to become global leader in eye care with projected $1 billion in sales by 2028.
• Opus GeneticscoreTechnology or Integration · 1 January 2021Global licensing agreement granting Viatris exclusive U.S. commercial rights to phentolamine ophthalmic solution 0.75%, a treatment for presbyopia and visual disturbances. Viatris provided independent educational grant for symposium at ASCRS 2026. Positive Phase 3 results from VEGA-3, MIRA-2, and LYNX-2 trials presented.
• Theravance BiopharmacoreChannel Partner/ Reseller/ DistributorYUPELRI collaboration for COPD treatment in the U.S. Viatris markets the product with Theravance reporting $17.7 million in Viatris collaboration revenue in Q1 2026 (up 15% year-over-year). Settlement with Mankind Pharma sets licensed launch date for April 23, 2039.
• Novo NordiskminorChannel Partner/ Reseller/ DistributorLexicon Pharmaceuticals partnership with Novo Nordisk for LX9851 obesity program; Viatris retains ex-U.S./Europe sotagliflozin rights through prior arrangement, demonstrating Viatris's involvement in cardiometabolic collaborations.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Pfizer: Pfizer is the originator of the Upjohn business that combined with Mylan to form Viatris in 2020. As a broad incumbent, Pfizer still commercializes overlapping cardiovascular and CNS brands and competes in the same payer/prescriber channels globally.
• Novartis: Novartis is the parent of Sandoz and a broad incumbent in branded pharmaceuticals. Viatris competes with Novartis's branded cardiovascular and CNS portfolio while partnering with Novartis entities on adjacent assets like the Theravance YUPELRI collaboration.

Direct peers

• Lupin Pharmaceuticals: Lupin is an India-based branded generics and complex generics manufacturer competing directly with Viatris in respiratory, cardiovascular, CNS, and women's health therapeutic areas. Both companies have significant US generics businesses with similar PBM dynamics.
• Cipla: Cipla is a major India-based pharmaceutical company competing with Viatris in respiratory, cardiovascular, and HIV therapies globally, with strong emerging market presence. Both target similar patient populations across 100+ countries.
• Sun Pharmaceutical Industries: Sun Pharma is explicitly named alongside Viatris as a top-tier branded generics competitor. Both companies rely heavily on emerging market volume, particularly in India where branded generics dominate 70-80% of the market.
• Teva Pharmaceutical Industries: Teva is the world's largest generics manufacturer and a direct competitor to Viatris in both generics and branded generics across multiple therapeutic areas including CNS, respiratory, and cardiovascular. Both companies operate global manufacturing footprints and compete head-to-head on portfolio breadth.
• Dr. Reddy's Laboratories: Dr. Reddy's is a leading India-headquartered generics and branded generics manufacturer with global operations overlapping Viatris's therapeutic areas including cardiovascular, CNS, and oncology supportive care. Both companies target PBM formulary access in the US and emerging market expansion.
• Sandoz: Sandoz is the Novartis generics and biosimilars spinoff, making it a direct competitor to Viatris's generics and biosimilars portfolio globally. Both serve the same PBM, pharmacy, and institutional channels across North America, Europe, and emerging markets.
• Aurobindo Pharma: Aurobindo is a large India-based generics manufacturer competing with Viatris in US generics, injectables, and emerging markets. Both companies pursue similar scale-driven strategies in API vertical integration and complex generics.

Emerging players

• Theravance Biopharma: Theravance is Viatris's YUPELRI collaboration partner for COPD and has an indirect royalty relationship through GSK's TRELEGY. Theravance's focus on specialty respiratory and GI overlaps with Viatris's commercial infrastructure utilization strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks2 records

Key highlights7 records

Customer concentration

• Xx.com/viatrisinc
• YouTubeyoutube.com/c/Viatris
• LinkedInlinkedin.com/company/viatris
• Instagraminstagram.com/viatrisinc

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries4 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Viatris